Valeant Pharm (VRX) said VISER1 study did not meet the non-inferiority efficacy endpoint on an overall intent-to-treat basis
Tweet Send to a Friend
Pharmaceuticals International (NYSE: VRX) reported summary results of VISER1, the first of two Phase 3 pivotal trials, for Viramidine. The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
